{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:53Z","timestamp":1789726373250,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10096-025-05173-x","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T13:55:35Z","timestamp":1748008535000},"page":"1835-1848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fosfomycin for the treatment of patients with bacterial prostatitis: a systematic review"],"prefix":"10.1007","volume":"44","author":[{"given":"Dimitrios S.","family":"Kontogiannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eleni","family":"Agoranou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios M.","family":"Skouteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"6","key":"5173_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.urology.2004.01.042","volume":"63","author":"JA Turner","year":"2004","unstructured":"Turner JA, Ciol MA, Von Korff M, Rothman I, Berger RE (2004) Healthcare use and costs of primary and secondary care patients with prostatitis. Urology 63(6):1031\u20131035","journal-title":"Urology"},{"key":"5173_CR2","doi-asserted-by":"crossref","unstructured":"Bouiller K, Zayet S, Lalloz PE, Potron A, Gendrin V, Chirouze C et al (2022) Efficacy and safety of oral Fosfomycin-Trometamol in male urinary tract infections with Multidrug-Resistant enterobacterales. Antibiot Basel Switz.;11(2)","DOI":"10.3390\/antibiotics11020198"},{"issue":"3","key":"5173_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jama.282.3.236","volume":"282","author":"JN Krieger","year":"1999","unstructured":"Krieger JN, Nyberg J, Leroy, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282(3):236\u2013237","journal-title":"JAMA"},{"issue":"4","key":"5173_CR4","doi-asserted-by":"publisher","first-page":"106106","DOI":"10.1016\/j.ijantimicag.2020.106106","volume":"56","author":"ACF Kwan","year":"2020","unstructured":"Kwan ACF, Beahm NP (2020) Fosfomycin for bacterial prostatitis: a review. Int J Antimicrob Agents 56(4):106106","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"5173_CR5","first-page":"71","volume":"79","author":"S Mazzoli","year":"2007","unstructured":"Mazzoli S (2007) Conventional bacteriology in prostatitis patients: Microbiological bias, problems and epidemiology on 1686 microbial isolates. Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol 79(2):71\u201375","journal-title":"Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol"},{"issue":"7","key":"5173_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/cid\/civ436","volume":"61","author":"ML Grayson","year":"2015","unstructured":"Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH et al (2015) Fosfomycin for treatment of prostatitis: new tricks for old dogs. Clin Infect Dis 61(7):1141\u20131143","journal-title":"Clin Infect Dis"},{"issue":"12","key":"5173_CR7","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1086\/652861","volume":"50","author":"BA Lipsky","year":"2010","unstructured":"Lipsky BA, Byren I, Hoey CT (2010) Treatment of bacterial prostatitis. Clin Infect Dis Off Publ Infect Dis Soc Am 50(12):1641\u20131652","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"5173_CR8","doi-asserted-by":"crossref","unstructured":"Marquez-Algaba E, Pigrau C, Bosch-Nicolau P, Vi\u00f1ado B, Serra-Pladevall J, Almirante B et al (2021) Risk factors for relapse in acute bacterial prostatitis: the impact of antibiotic regimens. Microbiol Spectr 9(2):e00534\u2013e00521","DOI":"10.1128\/Spectrum.00534-21"},{"key":"5173_CR9","first-page":"1404813","volume":"2018","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Zhanel MA, Karlowsky JA (2018) Oral fosfomycin for the treatment of acute and chronic bacterial prostatitis caused by Multidrug-Resistant Escherichia coli. Can J Infect Dis Med Microbiol J Can Mal Infect Microbiol Medicale 2018:1404813","journal-title":"Can J Infect Dis Med Microbiol J Can Mal Infect Microbiol Medicale"},{"issue":"6","key":"5173_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000074526","volume":"49","author":"K Charalabopoulos","year":"2003","unstructured":"Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N (2003) Penetration of antimicrobial agents into the prostate. Chemotherapy 49(6):269\u2013279","journal-title":"Chemotherapy"},{"issue":"4","key":"5173_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/idr14040067","volume":"14","author":"A Marino","year":"2022","unstructured":"Marino A, Stracquadanio S, Bellanca CM, Augello E, Ceccarelli M, Cantarella G et al (2022) Oral fosfomycin formulation in bacterial prostatitis: new role for an old Molecule-Brief literature review and clinical considerations. Infect Dis Rep 14(4):621\u2013634","journal-title":"Infect Dis Rep"},{"issue":"3","key":"5173_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s12088-024-01293-8","volume":"64","author":"S Dubey","year":"2024","unstructured":"Dubey S, Siddiqui AH, Sharma M (2024) The impact of fosfomycin on gram negative infections: A comprehensive review. Indian J Microbiol 64(3):846\u2013858","journal-title":"Indian J Microbiol"},{"issue":"1","key":"5173_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","volume":"18","author":"R Raz","year":"2012","unstructured":"Raz R (2012) Fosfomycin: an old\u2014new antibiotic. Clin Microbiol Infect 18(1):4\u20137","journal-title":"Clin Microbiol Infect"},{"key":"5173_CR14","doi-asserted-by":"crossref","unstructured":"Liu P, Chen S, Wu Z, ying, Qi M, Li X, yang, Liu C (2020) xia. Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist.;22:238\u201343","DOI":"10.1016\/j.jgar.2019.12.019"},{"key":"5173_CR15","doi-asserted-by":"publisher","first-page":"816806","DOI":"10.3389\/fmicb.2022.816806","volume":"13","author":"YP Wang","year":"2022","unstructured":"Wang YP, Chen YH, Hung IC, Chu PH, Chang YH, Lin YT et al (2022) Transporter genes and FosA associated with fosfomycin resistance in Carbapenem-Resistant Klebsiella pneumoniae. Front Microbiol 13:816806","journal-title":"Front Microbiol"},{"issue":"4","key":"5173_CR16","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/cid\/cit704","volume":"58","author":"BJ Gardiner","year":"2014","unstructured":"Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT et al (2014) Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis Off Publ Infect Dis Soc Am 58(4):e101\u2013105","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"5173_CR17","unstructured":"Aggarwal N, Leslie SW, Lotfollahzadeh S Recurrent Urinary Tract Infections. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Nov 11]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557479\/"},{"key":"5173_CR18","unstructured":"Cai T (2021) Recurrent uncomplicated urinary tract infections: definitions and risk factors. GMS Infect Dis 9Doc03 [Internet]. May 27 [cited 2024 Nov 11]; Available from: https:\/\/www.egms.de\/en\/journals\/id\/2021-9\/id000072.shtml"},{"issue":"5","key":"5173_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1086\/427507","volume":"40","author":"LE Nicolle","year":"2005","unstructured":"Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM et al (2005) Infectious diseases society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis Off Publ Infect Dis Soc Am 40(5):643\u2013654","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"5173_CR20","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0 (2025) https:\/\/www.eucast.org[Internet]. [cited 2025 Jan 13]. Available from: https:\/\/www.eucast.org\/clinical_breakpoints"},{"issue":"6","key":"5173_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377\u2013384","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"5173_CR22","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev 18(2):e1230","journal-title":"Campbell Syst Rev"},{"issue":"1","key":"5173_CR23","doi-asserted-by":"publisher","first-page":"105935","DOI":"10.1016\/j.ijantimicag.2020.105935","volume":"56","author":"T Cai","year":"2020","unstructured":"Cai T, Tamanini I, Mattevi D, Verze P, Palmieri A, Malossini G et al (2020) Fosfomycin Trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: results of a pilot study. Int J Antimicrob Agents 56(1):105935","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"5173_CR24","doi-asserted-by":"publisher","first-page":"e0213623","DOI":"10.1128\/spectrum.02136-23","volume":"11","author":"J Burgos","year":"2023","unstructured":"Burgos J, Hoyos-Mallecot Y, Ferre-Losa C, Arando M, Monforte A, Pumarola T et al (2023) Oral fosfomycin for treatment of acute bacterial prostatitis caused by multidrug-resistant enterobacterales. Microbiol Spectr 11(5):e0213623","journal-title":"Microbiol Spectr"},{"issue":"5","key":"5173_CR25","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1093\/jac\/dkz015","volume":"74","author":"I Karaiskos","year":"2019","unstructured":"Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D et al (2019) Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother 74(5):1430\u20131437","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"5173_CR26","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1128\/AAC.02611-15","volume":"60","author":"I Los-Arcos","year":"2016","unstructured":"Los-Arcos I, Pigrau C, Rodr\u00edguez-Pardo D, Fern\u00e1ndez-Hidalgo N, Andreu A, Larrosa N et al (2016) Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis. Antimicrob Agents Chemother 60(3):1854\u20131858","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5173_CR27","doi-asserted-by":"publisher","first-page":"107182","DOI":"10.1016\/j.ijantimicag.2024.107182","volume":"63","author":"S Fukushima","year":"2024","unstructured":"Fukushima S, Otsuka Y, Hagiya H, Nishikawa N, Otsuka F (2024) Prostate abscess caused by ESBL-producing Escherichia coli successfully treated with fosfomycin monotherapy. Int J Antimicrob Agents 63(6):107182","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"5173_CR28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/21681805.2021.1933170","volume":"55","author":"E Denes","year":"2021","unstructured":"Denes E (2021) Prolonged course of Fosfomycin-Trometamol for chronic prostatitis: an unknown good option. Scand J Urol 55(4):344\u2013345","journal-title":"Scand J Urol"},{"issue":"5","key":"5173_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ijantimicag.2016.02.009","volume":"47","author":"J Gian","year":"2016","unstructured":"Gian J, Cunha BA (2016) Raoultella planticola chronic bacterial prostatitis with prostatic calcifications: successful treatment with prolonged fosfomycin therapy. Int J Antimicrob Agents 47(5):414","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"5173_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ijantimicag.2014.12.019","volume":"45","author":"BA Cunha","year":"2015","unstructured":"Cunha BA, Gran A, Raza M (2015) Persistent extended-spectrum \u03b2-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and Doxycycline. Int J Antimicrob Agents 45(4):427\u2013429","journal-title":"Int J Antimicrob Agents"},{"issue":"22","key":"5173_CR31","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2169\/internalmedicine.53.3098","volume":"53","author":"H Hagiya","year":"2014","unstructured":"Hagiya H, Ninagawa M, Hasegawa K, Terasaka T, Kimura K, Waseda K et al (2014) Fosfomycin for the treatment of prostate infection. Intern Med Tokyo Jpn 53(22):2643\u20132646","journal-title":"Intern Med Tokyo Jpn"},{"key":"5173_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1186\/1471-2334-14-466","volume":"14","author":"M Dubos","year":"2014","unstructured":"Dubos M, Barraud O, Fedou AL, Fredon F, Laurent F, Brakbi Y et al (2014) Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin. BMC Infect Dis 14:466","journal-title":"BMC Infect Dis"},{"issue":"2","key":"5173_CR33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3201\/eid1702.101313","volume":"17","author":"G Peirano","year":"2011","unstructured":"Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD (2011) New Delhi metallo-beta-lactamase from traveler returning to Canada. Emerg Infect Dis 17(2):242\u2013244","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"5173_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki280","volume":"56","author":"F Guerin","year":"2005","unstructured":"Guerin F, Henegar C, Spiridon G, Launay O, Salmon-Ceron D, Poyart C (2005) Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-{beta}-lactamase gene from Saudi Arabia. J Antimicrob Chemother 56(3):601\u2013602","journal-title":"J Antimicrob Chemother"},{"key":"5173_CR35","doi-asserted-by":"publisher","first-page":"e00493","DOI":"10.1016\/j.idcr.2019.e00493","volume":"15","author":"F Almeida","year":"2019","unstructured":"Almeida F, Santos Silva A, Silva Pinto A, Sarmento A (2019) Chronic prostatitis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli managed using oral fosfomycin-A case report. IDCases 15:e00493","journal-title":"IDCases"},{"issue":"4","key":"5173_CR36","first-page":"358","volume":"29","author":"M Tang","year":"2023","unstructured":"Tang M, Ip WCT, Yuen JKY, Shea YF (2023) Chronic prostatitis with recurrent extended-spectrum beta-lactamase\u2013producing Escherichia coli bacteraemia treated with prolonged fosfomycin. Hong Kong Med J 29(4):358.e1-358.e2","journal-title":"Hong Kong Med J"},{"issue":"1","key":"5173_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","volume":"48","author":"MP Veve","year":"2016","unstructured":"Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL (2016) Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections. Int J Antimicrob Agents 48(1):56\u201360","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"5173_CR38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7164\/antibiotics.39.141","volume":"39","author":"K Suzuki","year":"1986","unstructured":"Suzuki K, Tamai H (1986) [Investigation on effectiveness and safety of fosfomycin in treatment of patients with allergy induced by antibacterial agents]. Jpn J Antibiot 39(1):141\u2013153","journal-title":"Jpn J Antibiot"},{"key":"5173_CR39","unstructured":"Yoo TK, Kim SW, Kwak HG, Han SH, Park RJ (1995) Treatment of chronic prostatitis by intraprostatic injection of fosfomycin: 6 years\u2019 experience. Korean J Urol.;294\u2013298"},{"key":"5173_CR40","unstructured":"Park KS, Hahm KJ (1988) The effect of the direct injection of fosfomycin sodium into prostate in chronic bacterial prostatitis. Korean J Urol.;453\u2013458"},{"key":"5173_CR41","doi-asserted-by":"publisher","first-page":"1243824","DOI":"10.3389\/fphar.2023.1243824","volume":"14","author":"AV Johri","year":"2023","unstructured":"Johri AV, Johri P, Hoyle N, Nadareishvili L, Pipia L, Nizharadze D (2023) Case report: successful treatment of recurrent E. coli infection with bacteriophage therapy for patient suffering from chronic bacterial prostatitis. Front Pharmacol 14:1243824","journal-title":"Front Pharmacol"},{"key":"5173_CR42","unstructured":"Burgos J (2024) May Clinical Efficacy of oral Fosfomycin Trometamol and Cefixime in the Treatment of Acute Bacterial Prostatitis (CEFOSPROST): a comparative, randomized, open, multicenter trial [Internet]. Clinical Trials Information System; Report No.: CTIS2024-513465-39\u201300. Available from: https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT=2024-513465-39-00"},{"key":"5173_CR43","unstructured":"Arora D, Dubey R, Phase III (2022) Aug Clinical Trial to evaluate Efficacy, Safety and Tolerability of Fosfomycin (Trometamol) Powder 3\u00a0g versus Ciprofloxacin Tablets 750\u00a0mg in patients with Chronic Bacterial Prostatitis [Internet]. Clinical Trials Registry - India; Report No.: CTRI\/2022\/08\/045068. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2022\/08\/045068"},{"key":"5173_CR44","doi-asserted-by":"crossref","unstructured":"Kamath M, Johns ST, Ma A, Mehta S (2020) 1690. Oral fosfomycin for the treatment of bacterial prostatitis. Open forum infectious diseases. Oxford University Press, p S829","DOI":"10.1093\/ofid\/ofaa439.1868"},{"issue":"4","key":"5173_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/wasj.2022.161","volume":"4","author":"A Marino","year":"2022","unstructured":"Marino A, Stracquadanio S, Ceccarelli M, Zagami A, Nunnari G, Cacopardo B (2022) Oral fosfomycin formulation for acute bacterial prostatitis; a new role for an old molecule: A case report and brief literature review. World Acad Sci J 4(4):1\u20136","journal-title":"World Acad Sci J"},{"issue":"2","key":"5173_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1128\/iai.28.2.393-397.1980","volume":"28","author":"PD Ward","year":"1980","unstructured":"Ward PD, Turner WH (1980) Identification of Staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. Infect Immun 28(2):393\u2013397","journal-title":"Infect Immun"},{"issue":"12","key":"5173_CR47","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.1128\/AAC.01071-15","volume":"59","author":"S Sastry","year":"2015","unstructured":"Sastry S, Clarke LG, Alrowais H, Querry AM, Shutt KA, Doi Y (2015) Clinical appraisal of fosfomycin in the era of antimicrobial resistance. Antimicrob Agents Chemother 59(12):7355\u20137361","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"5173_CR48","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/antibiotics9080511","volume":"9","author":"M Fajfr","year":"2020","unstructured":"Fajfr M, Balik M, Cermakova E, Bostik P (2020) Effective treatment for uncomplicated urinary tract infections with oral fosfomycin, single center four year retrospective study. Antibiotics 9(8):511","journal-title":"Antibiotics"},{"issue":"6","key":"5173_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s10156-010-0079-z","volume":"16","author":"N Ceran","year":"2010","unstructured":"Ceran N, Mert D, Kocdogan FY, Erdem I, Ozyurek S, Goktas P et al (2010) A randomized comparative study of single-dose fosfomycin and 5-day Ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother 16(6):424\u2013430","journal-title":"J Infect Chemother"},{"issue":"5","key":"5173_CR50","first-page":"911","volume":"59","author":"HM Gu","year":"2023","unstructured":"Gu HM, Gu JS, Chung HS, Jung SI, Kwon D, Kim MH et al (2023) Fosfomycin for antibiotic prophylaxis in men undergoing a transrectal prostate biopsy: A systematic review and Meta-Analysis. Med (Mex) 59(5):911","journal-title":"Med (Mex)"},{"issue":"2","key":"5173_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/2090598X.2019.1592636","volume":"17","author":"DM Freitas","year":"2019","unstructured":"Freitas DM, de O, Moreira DM (2019) Fosfomycin Trometamol vs Ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: A meta-analysis of clinical studies. Arab J Urol 17(2):114\u2013119","journal-title":"Arab J Urol"},{"issue":"4","key":"5173_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000502851","volume":"103","author":"C D\u2019Elia","year":"2019","unstructured":"D\u2019Elia C, Mian C, Hanspeter E, Ladurner C, Palermo SM, Pycha S et al (2019) Efficacy and safety of two fosfomycin regimens as antimicrobial prophylaxis for transrectal prostate biopsy: A randomised study. Urol Int 103(4):433\u2013438","journal-title":"Urol Int"},{"issue":"2","key":"5173_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41391-018-0032-2","volume":"21","author":"J Noreikaite","year":"2018","unstructured":"Noreikaite J, Jones P, Fitzpatrick J, Amitharaj R, Pietropaolo A, Vasdev N et al (2018) Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 21(2):153\u2013160","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"5173_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","volume":"10","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE (2010) Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10(1):43\u201350","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"5173_CR55","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","volume":"31","author":"G Samonis","year":"2012","unstructured":"Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME (2012) Synergy of fosfomycin with carbapenems, colistin, Netilmicin, and Tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 31(5):695\u2013701","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"issue":"12","key":"5173_CR56","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3390\/pathogens11121441","volume":"11","author":"B Kowalska-Krochmal","year":"2022","unstructured":"Kowalska-Krochmal B, M\u0105czy\u0144ska B, Rura\u0144ska-Smutnicka D, Secewicz A, Krochmal G, Bartelak M et al (2022) Assessment of the susceptibility of clinical Gram-Negative and Gram-Positive bacterial strains to fosfomycin and significance of this antibiotic in infection treatment. Pathog Basel Switz 11(12):1441","journal-title":"Pathog Basel Switz"},{"issue":"2","key":"5173_CR57","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/jac\/dkr466","volume":"67","author":"DE Karageorgopoulos","year":"2012","unstructured":"Karageorgopoulos DE, Wang R, Yu XH, Falagas ME (2012) Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 67(2):255\u2013268","journal-title":"J Antimicrob Chemother"},{"key":"5173_CR58","doi-asserted-by":"crossref","unstructured":"Gautier-Bouchardon AV (2018) Antimicrobial resistance in Mycoplasma spp. Microbiol Spectr.;6(4)","DOI":"10.1128\/microbiolspec.ARBA-0030-2018"},{"issue":"3","key":"5173_CR59","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ijantimicag.2015.05.007","volume":"46","author":"LD Tesh","year":"2015","unstructured":"Tesh LD, Shaeer KM, Cho JC, Estrada SJ, Huang V, Bland CM et al (2015) Neisseria gonorrhoeae and fosfomycin: past, present and future. Int J Antimicrob Agents 46(3):290\u2013296","journal-title":"Int J Antimicrob Agents"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05173-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:18:22Z","timestamp":1757179102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05173-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["5173"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05173-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}